MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

Original reporting
Published Nov 16, 2026, 12:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary — source image
Decision brief

The 30-second read

$MPLTBearishMed
01

Why it matters

The earnings miss may trigger short‑term sell pressure, but the company's cash position and upcoming trial milestones provide a longer‑term catalyst.

02

Market read

Earnings surprise in a small‑cap biotech; traders may adjust positions ahead of upcoming trial data releases.

03

What to watch

Potential upside from upcoming Phase 3 schizophrenia trial and Phase 2 VISTA results could offset short‑term earnings pain.

Relevance 7/10Novelty 7/10Timing: post‑market filing

Background

MapLight Therapeutics filed its Q3 2026 10‑Q, highlighting increased R&D spend, a widened net loss, and cash sufficient through 2028.

Company-level read

Ticker impact

$MPLTBearishHigh confidence
Context

MapLight Therapeutics reported a widened net loss and a $0.97 loss per share for Q3 2026 in its 10‑Q filing.

Expected impact

likely downward pressure as investors price in higher expenses and a larger loss.

Evidence & confidence

Quarterly earnings surprise with a 75% increase in net loss typically triggers a sell‑off in small‑cap biotech stocks.

Market effects

Biotech sector may see broader risk‑off sentiment as earnings disappointment spreads.

US small‑cap biotech indices could dip modestly.

Limited to investors tracking biotech pipelines and cash‑runway concerns.

Counterpoint

Long‑term investors may view the cash runway through 2028 as a buying opportunity despite the near‑term loss.

Key entities

  • MapLight Therapeutics

    Biopharmaceutical company developing treatments for schizophrenia and Alzheimer's disease psychosis.

Related articles

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and